Comprehensive Stock Comparison
Compare YD Bio Limited Ordinary Shares (YDES) vs Adaptive Biotechnologies Corporation (ADPT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  YDES | 45.8% revenue growth vs ADPT's 5.1% |
| Quality / Margins |  ADPT | -31.5% net margin vs YDES's -276.6% |
| Stability / Safety | ADPT | Beta 1.31 vs YDES's 1.64 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ADPT | +93.4% vs YDES's -27.7% |
| Efficiency (ROA) | ADPT | -16.2% ROA vs YDES's -100.8%, ROIC -41.6% vs -63.3% |
Who Each Stock Is For
Income & stability
ADPTbeta 1.31
Growth exposure
YDESRev growth 45.8%
Long-term compounding (10Y)
YDES-27.7% 10Y total return vs ADPT's -61.0%
Sleep-well-at-night portfolio
YDESLower volatility, beta 1.64, Low D/E 0.3%, current ratio 13.18x
Defensive / Recession hedge
ADPTBeta 1.31, current ratio 2.89x
Business Model
What each company does and how it makes money
YD Bio is a clinical-stage biopharmaceutical company developing exosome-based therapeutics for cancer prevention and treatment. It generates revenue primarily through research grants and partnerships — with future income expected from drug licensing and commercialization — though it's currently in pre-revenue stages as it advances its pipeline. The company's competitive advantage lies in its proprietary exosome technology platform, which targets diseases with significant unmet medical needs.
Adaptive Biotechnologies is a biotechnology company that develops immune medicine platforms for diagnosing and treating diseases like cancer, autoimmune disorders, and infectious diseases. It generates revenue primarily through its clinical diagnostics segment — including its clonoSEQ test for minimal residual disease monitoring — and its translational and clinical genomics research services, with diagnostics contributing roughly 60% of revenue. The company's key advantage lies in its proprietary immune medicine platform that maps and translates the genetics of the adaptive immune system into clinical diagnostics and therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADPT 4YDES 1ADPT5/5 metricsYDES2/3 metricsADPT6/9 metricsADPT4/6 metricsADPT2/2 metricsADPT leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). YDES leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
ADPT and YDES operate at a comparable scale, with $253M and $0 in trailing revenue. Profitability is closely matched — net margins range from -31.5% (ADPT) to -2.8% (YDES).
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $253M |
| EBITDAEarnings before interest/tax | -$3M | -$62M |
| Net IncomeAfter-tax profit | -$3M | -$80M |
| Free Cash FlowCash after capex | -$1M | -$63M |
| Gross MarginGross profit ÷ Revenue | +30.4% | +71.8% |
| Operating MarginEBIT ÷ Revenue | -2.9% | -30.9% |
| Net MarginNet income ÷ Revenue | -2.8% | -31.5% |
| FCF MarginFCF ÷ Revenue | -9.3% | -24.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +102.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -116.0% | +126.6% |
Valuation Metrics
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| Market CapShares × price | $614M | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $610M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -15.54x | -14.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1202.16x | 13.39x |
| Price / BookPrice ÷ Book value/share | 5.47x | 11.41x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ADPT delivers a -39.0% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-43 for YDES. YDES carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADPT's 0.44x. On the Piotroski fundamental quality scale (0–9), ADPT scores 4/9 vs YDES's 3/9, reflecting mixed financial health.
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| ROE (TTM)Return on equity | -42.7% | -39.0% |
| ROA (TTM)Return on assets | -100.8% | -16.2% |
| ROICReturn on invested capital | -63.3% | -41.6% |
| ROCEReturn on capital employed | -44.1% | -32.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.44x |
| Net DebtTotal debt minus cash | -$3M | $41M |
| Cash & Equiv.Liquid assets | $3M | $48M |
| Total DebtShort + long-term debt | $22,555 | $89M |
| Interest CoverageEBIT ÷ Interest expense | -1893.69x | -6.25x |
Total Returns (with DRIP)
A $10,000 investment in YDES five years ago would be worth $7,226 today (with dividends reinvested), compared to $3,594 for ADPT. Over the past 12 months, ADPT leads with a +93.4% total return vs YDES's -27.7%. The 3-year compound annual growth rate (CAGR) favors ADPT at 22.9% vs YDES's -10.3% — a key indicator of consistent wealth creation.
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| YTD ReturnYear-to-date | -27.5% | -1.3% |
| 1-Year ReturnPast 12 months | -27.7% | +93.4% |
| 3-Year ReturnCumulative with dividends | -27.7% | +85.6% |
| 5-Year ReturnCumulative with dividends | -27.7% | -64.1% |
| 10-Year ReturnCumulative with dividends | -27.7% | -61.0% |
| CAGR (3Y)Annualised 3-year return | -10.3% | +22.9% |
Risk & Volatility
ADPT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than YDES's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADPT currently trades 75.6% from its 52-week high vs YDES's 34.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 1.31x |
| 52-Week HighHighest price in past year | $25.00 | $20.76 |
| 52-Week LowLowest price in past year | $5.30 | $6.26 |
| % of 52W HighCurrent price vs 52-week peak | +34.8% | +75.6% |
| RSI (14)Momentum oscillator 0–100 | 36.8 | 45.1 |
| Avg Volume (50D)Average daily shares traded | 39K | 1.6M |
Analyst Outlook
| Metric | YDESYD Bio Limited Or… | ADPTAdaptive Biotechn… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $21.25 |
| # AnalystsCovering analysts | — | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | $0.00 | $510360.00 | — |
| Adaptive Biotechnol… (ADPT) | $38M | $179M | +365.5% |
Adaptive Biotechnologies Corporation's revenue grew from $38M (2017) to $179M (2024) — a 24.6% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | 3.9% | -2.8% | -171.4% |
| Adaptive Biotechnol… (ADPT) | -111.4% | -89.1% | +20.0% |
Adaptive Biotechnologies Corporation's net margin went from -111% (2017) to -89% (2024).
Chart 3EPS Growth — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | -0.17 | -0.56 | -229.4% |
| Adaptive Biotechnol… (ADPT) | -0.41 | -1.08 | -163.4% |
Adaptive Biotechnologies Corporation's EPS grew from $-0.41 (2017) to $-1.08 (2024).
Chart 4Free Cash Flow — 5 Years
YD Bio Limited Ordinary Shares generated $-5M FCF in 2024 (-590% vs 2021). Adaptive Biotechnologies Corporation generated $-99M FCF in 2024 (+61% vs 2021).
YDES vs ADPT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is YDES or ADPT a better buy right now?
Analysts rate Adaptive Biotechnologies Corporation (ADPT) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YDES or ADPT?
Over the past 5 years, YD Bio Limited Ordinary Shares (YDES) delivered a total return of -27.7%, compared to -64.1% for Adaptive Biotechnologies Corporation (ADPT). A $10,000 investment in YDES five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: YDES returned -27.7% versus ADPT's -61.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YDES or ADPT?
By beta (market sensitivity over 5 years), Adaptive Biotechnologies Corporation (ADPT) is the lower-risk stock at 1.31β versus YD Bio Limited Ordinary Shares's 1.64β — meaning YDES is approximately 25% more volatile than ADPT relative to the S&P 500. On balance sheet safety, YD Bio Limited Ordinary Shares (YDES) carries a lower debt/equity ratio of 0% versus 44% for Adaptive Biotechnologies Corporation — giving it more financial flexibility in a downturn.
04Which has better profit margins — YDES or ADPT?
Adaptive Biotechnologies Corporation (ADPT) is the more profitable company, earning -89.1% net margin versus -276.6% for YD Bio Limited Ordinary Shares — meaning it keeps -89.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADPT leads at -90.8% versus -286.5% for YDES. At the gross margin level — before operating expenses — ADPT leads at 59.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — YDES or ADPT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is YDES or ADPT better for a retirement portfolio?
For long-horizon retirement investors, Adaptive Biotechnologies Corporation (ADPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. YD Bio Limited Ordinary Shares (YDES) carries a higher beta of 1.64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADPT: -61.0%, YDES: -27.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between YDES and ADPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.